Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC1A3 | P43003 | 5/20 | 0.48 |
| ▸ | SLC1A2 | P43004 | 5/20 | 0.48 |
| ▸ | SLC1A1 | P43005 | 5/20 | 0.48 |
| ▸ | LTA4H | P09960 | 7/20 | 0.46 |
| ▸ | KIF11 | P52732 | 2/20 | 0.43 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.41 |
| ▸ | SPHK1 | Q9NYA1 | 5/20 | 0.40 |
| ▸ | SPHK2 | Q9NRA0 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17531810 | 1.00 | SLC1A3 (0.48) | SLC1A3SLC1A2SLC1A1LTA4HKIF11 | |
| SCHEMBL22070158 | 0.83 | TAAR1 (0.46) | SLC1A3SLC1A2SLC1A1LTA4HKIF11 | |
| SCHEMBL22076705 | 0.83 | LTA4H (0.45) | SLC1A3SLC1A2SLC1A1LTA4HHDAC8 | |
| SCHEMBL17531778 | 0.80 | TAAR1 (0.43) | SLC1A3SLC1A2SLC1A1LTA4H | |
| SCHEMBL17531775 | 0.79 | POLB (0.49) | HDAC8 | |
| SCHEMBL22070168 | 0.78 | KIF11 (0.38) | SLC1A3SLC1A2SLC1A1LTA4HKIF11 | |
| SCHEMBL17300186 | 0.78 | SPHK1 (0.49) | SLC1A3SLC1A2SLC1A1LTA4HSPHK1 | |
| SCHEMBL31045317 | 0.77 | HDAC8 (0.52) | HDAC8 | |
| SCHEMBL30101855 | 0.77 | SLC1A3 (0.42) | SLC1A3SLC1A2SLC1A1KIF11 | |
| SCHEMBL31142119 | 0.77 | SLC1A3 (0.42) | SLC1A3SLC1A2SLC1A1KIF11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230158141-A1 | Conjugates of Biomolecule and Use Thereof | YAFEI SHANGHAI BIOLOG MEDICINE SCIENCE & TECHNOLOG (CN) | 2023-05-25 | — | — | US | disclosed |
| EP-4108675-A1 | PREPARATION AND USE OF IMMUNOSTIMULATORY COUPLING COMPLEX WHICH IS DELIVERED AND ACTIVATED IN TARGETED MANNER | Yafei Shanghai Biolog Medicine Science & Technology Co., Ltd. (CN) | 2022-12-28 | — | — | EP | disclosed |
| US-20200247842-A1 | Immune-stimulating soluble doxorubicin-conjugated complex | YAFEI (SHANGHAI) BIOPHARMACEUTICAL CO LTD (CN) | 2020-08-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200247842-A1 | Immune-stimulating soluble doxorubicin-conjugated complex | TLR3, CD40, TLR6 | SLC1A3 3268/4885SLC1A2 3582/4885SLC1A1 3449/4885 |
| US-20230158141-A1 | Conjugates of Biomolecule and Use Thereof | CD47, FCGR2A, CD40 | SLC1A3 3604/4885SLC1A2 3497/4885SLC1A1 3580/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.